WO2019209078A1 - 신규한 융합 단백질 및 이를 포함하는 암의 예방 또는 치료용 약학적 조성물 - Google Patents

신규한 융합 단백질 및 이를 포함하는 암의 예방 또는 치료용 약학적 조성물 Download PDF

Info

Publication number
WO2019209078A1
WO2019209078A1 PCT/KR2019/005096 KR2019005096W WO2019209078A1 WO 2019209078 A1 WO2019209078 A1 WO 2019209078A1 KR 2019005096 W KR2019005096 W KR 2019005096W WO 2019209078 A1 WO2019209078 A1 WO 2019209078A1
Authority
WO
WIPO (PCT)
Prior art keywords
seq
cells
region
cancer
immunoglobulin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2019/005096
Other languages
English (en)
French (fr)
Korean (ko)
Inventor
김정호
김범석
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Good T Cells Inc
Original Assignee
Good T Cells Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Good T Cells Inc filed Critical Good T Cells Inc
Priority to EP19793399.7A priority Critical patent/EP3792276A4/en
Priority to CN201980028463.XA priority patent/CN112041333B/zh
Priority to JP2020559369A priority patent/JP7485368B2/ja
Priority to US17/050,816 priority patent/US11820801B2/en
Publication of WO2019209078A1 publication Critical patent/WO2019209078A1/ko
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Definitions

  • the present invention relates to a novel fusion protein comprising an extracellular domain and an immunoglobulin Fc region of leucine-rich and immunoglobulin-like domains 1 (Lrig-1) protein, and uses thereof.
  • Immunoglobulins comprise four polypeptide chains, ie two heavy and two light chains associated via interchain disulfide bonds. Each light chain has two domains, namely the variable light domain (VL) and the constant light chain domain (CL), and each heavy chain has two regions, namely the variable heavy chain region (VH) and the constant heavy chain region (CH).
  • the constant heavy chain region (CH) consists of the constant heavy chain region (e.g., CH1, CH2, CH3, etc.) designated by number (e.g., US 6,086,875 (Blumberg RS, et al.), US 5,624,821 (Winter GP et al.) And US 5,116,964 (Capon DJ and Lasky LA).
  • Immunoglobulins are classified into different isotypes (ie, IgG, IgM, IgA, IgD and IgE) based on their biological properties, their location in the organism and their ability to process different antigens.
  • the constant heavy chain region may have three or four CH domains.
  • the heavy chain in some isotypes (IgA, IgD and IgG), contains a hinge region that adds flexibility to the molecule (Janeway et al. 2001, Immunobiology, Garland Publishing, N.Y., N.Y.).
  • IgG1 In humans there are four IgG subclasses (IgG1, 2, 3, 4), which are named according to the order in which they are abundant in serum (IgG1 is most abundant).
  • the IgG isotype consists of two light chains and two heavy chains, each heavy chain comprising three constant heavy chain domains (CH1, CH2, CH3).
  • the two heavy chains of IgG are linked by disulfide bonds (-S-S-) to each other and to the light chain, respectively.
  • the antigen binding site of IgG is located in a fragment antigen binding region (Fab region) comprising the variable light (VL) and variable heavy (VH) domains as well as the constant light (CL) and constant heavy (CH1) domains.
  • the fragment crystallizable region (Fc region) of IgG is part of a heavy chain that contains CH2 and CH3 domains that bind Fc receptors found on the surface of certain cells, including neonatal Fc receptors (FcRn).
  • the heavy chain of IgG also has a hinge region (hinge) between CH1 and CH2, which separates the Fab region from the Fc region and joins the two heavy chains together via disulfide bonds.
  • the structure of the hinge region contributes to the unique biological properties of each of the four IgG subclasses.
  • IgG is secreted into small monomers that allow for easy perfusion of tissue. This is the only isotype with a receptor (newborn Fc receptor (FcRn)) that promotes passage through the human placenta to protect the fetus in the uterus. IgG absorbed through the placenta provides humoral immunity to newborns before their own immune system develops.
  • FcRn newborn Fc receptor
  • the IgG neonatal Fc receptor (FcRn) binding site is located in the Fc region of the antibody.
  • FcRn is generally expressed in human placental and epithelial cells and participates in the endocytosis salvage pathway that prevents the degradation of IgG. This salvage pathway is mediated by the high pH dependent binding affinity of IgG for FcRn at acidic pH.
  • the high affinity of IgG for FcRn at acidic pH is believed to induce binding of internalized IgG to FcRn after uptake into acidic endosomes (Goebl NA, et al., 2008; Junghans RP, et. al., 1996].
  • the salvage pathway provides one mechanism for the development of next generation protein drugs with extended half-lives in the blood circulation compared to unmodified protein drugs.
  • unmodified protein drugs have short circulatory half-lives and therefore require frequent administration over the long period of treatment required.
  • Extensive efforts have been made to extend the half-life of protein drugs by a number of methods, including PEGylated fusion protein technology (Food and Drug Administration, Osborn BL, et al., 2002). The result was not ideal.
  • One object of the present invention is to provide a novel fusion protein comprising an extracellular domain and an immunoglobulin Fc region of the leucine-rich and immunoglobulin-like domains 1 (Lrig-1) protein.
  • Another object of the invention relates to a nucleic acid molecule encoding said fusion protein according to the invention.
  • Still another object of the present invention is to provide an expression vector into which the nucleic acid molecule is inserted.
  • Still another object of the present invention is to provide a host cell line transfected with the expression vector according to the present invention.
  • Still another object of the present invention is to provide a pharmaceutical composition for preventing or treating cancer comprising the fusion protein according to the present invention.
  • the present invention relates to a fusion protein comprising an extracellular domain and an immunoglobulin Fc region of the leucine-rich and immunoglobulin-like domains 1 (Lrig-1) protein.
  • the "Lrig-1 protein” is a transmembrane protein consisting of 1091 amino acids present on the surface of regulatory T cells, leucine-rich repeat (LRR) and three extracellular or lumen side It consists of immunoglobulin-like domains, cell membrane penetration sequences and cytoplasmic tails.
  • the LRIG gene family includes LRIG1, LRIG2 and LRIG3, and the amino acids between them are highly conserved.
  • the extracellular domain of the Lrig-1 protein may be an extracellular domain of Lrig-1 protein derived from a mammal including a human, a primate such as a monkey, a mouse, a rodent such as a rat, and the like.
  • the extracellular domain of the Lrig-1 protein may be represented by SEQ ID NO: 1 corresponding to the 35 th to 794 amino acid sequences of the human-derived Lrig-1 protein, which is a nucleic acid represented by SEQ ID NO: 2 It may be encoded by the sequence, but is not limited thereto (see Table 1).
  • Sequence Listing Sequence information SEQ ID NO: 1 AGPRAPCAAACTCAGDSLDCGGRGLAALPGDLPSWTRSLNLSYNKLSEIDPAGFEDLPNLQEVYLNNNELTAVPSLGAASSHVVSLFLQHNKIRSVEGSQLKAYLSLEVLDLSLNNITEVRNTCFPHGPPIKELNLAGNRIGTLELGAFDGLSRSLLTLRLSKNRITQLPVRAFKLPRLTQLDLNRNRIRLIEGLTFQGLNSLEVLKLQRNNISKLTDGAFWGLSKMHVLHLEYNSLVEVNSGSLYGLTALHQLHLSNNSIARIHRKGWSFCQKLHELVLSFNNLTRLDEESLAELSSLSVLRLSHNSISHIAEGAFKGLRSLRVLDLDLDHNEISGTIEDTSGAFSGLDSLSKLTLFGNKIKSVAKRAFSGLEGLEHLNLGGNAIRSVQFDAFVKMKNLKELHISSDSFLCDCQLKWLPPWLIGRMLQAFVTATC
  • the extracellular domain of the Lrig-1 protein may be represented by SEQ ID NO: 3 corresponding to the 35th to 794th amino acid sequence of the mouse-derived Lrig-1 protein, which is a nucleic acid represented by SEQ ID NO: 4 It may be encoded by the sequence, but is not limited thereto (see Table 2).
  • immunoglobulin Fc region means a site including heavy chain constant region 2 (CH2) and / or heavy chain constant region 3 (CH3) moieties excluding the heavy and light chain variable regions of an immunoglobulin.
  • the immunoglobulin Fc region may be one component forming a moiety of the protein conjugate of the present invention.
  • the immunoglobulin Fc region may include a hinge portion in the heavy chain constant region, which may affect the structural flexibility of the final fusion protein, and may further increase productivity and stability of the fusion protein.
  • the present invention is not limited thereto.
  • the immunoglobulin Fc region of the present invention has a substantially equivalent or improved effect as the natural type, except for the heavy and light chain variable regions of the immunoglobulin, some or all heavy chain constant region 1 (CH1) and / or light chain constant region It may be an extended Fc region including 1 (CL1). It may also be a region from which some fairly long amino acid sequences corresponding to CH2 and / or CH3 have been removed.
  • CH1 heavy chain constant region 1
  • CL1 extended Fc region including 1
  • the immunoglobulin Fc regions of the present invention may comprise 1) CH1 domain, CH2 domain, CH3 domain and CH4 domain, 2) CH1 domain and CH2 domain, 3) CH1 domain and CH3 domain, 4) CH2 domain and CH3 domain, 5) Combination of one or two or more of the CH1 domain, CH2 domain, CH3 domain and CH4 domain with an immunoglobulin hinge region (or a portion of the hinge region), 6) heavy chain constant region may be a dimer of each domain and light chain constant region .
  • an immunoglobulin hinge region or a portion of the hinge region
  • immunoglobulin Fc regions of the present invention include naturally occurring amino acid sequences as well as sequence derivatives thereof.
  • Amino acid sequence derivatives mean that one or more amino acid residues in a natural amino acid sequence have different sequences by deletion, insertion, non-conservative or conservative substitution, or a combination thereof.
  • amino acid residues known to be important for binding can be used as suitable sites for modification.
  • various kinds of derivatives are possible, such as a site capable of forming disulfide bonds, a few amino acids at the N-terminus in the native Fc, or a methionine residue may be added at the N-terminus of the native Fc.
  • the complement binding site such as C1q binding site may be removed, ADCC (antibody dependent cell mediated cytotoxicity) site may be removed in order to eliminate the effector function.
  • ADCC antibody dependent cell mediated cytotoxicity
  • Amino acid exchanges in proteins and peptides that do not alter the activity of the molecule as a whole are known in the art (H. Neurode, R. L. Hill, The Proteins, Academic Press, New York, 1979).
  • the most commonly occurring exchanges are amino acid residues Ala / Ser, Val / Ile, Asp / Glu, Thr / Ser, Ala / Gly, Ala / Thr, Ser / Asn, Ala / Val, Ser / Gly, Thy / Phe, Ala / Exchange between Pro, Lys / Arg, Asp / Asn, Leu / Ile, Leu / Val, Ala / Glu, Asp / Gly.
  • it may be modified by phosphorylation, sulfation, acrylation, glycosylation, methylation, farnesylation, acetylation and amidation. may be modified.
  • Fc derivatives may exhibit biological activities equivalent to those of the Fc region of the present invention and may increase structural stability to heat, pH, etc. of the Fc region.
  • the Fc region may be obtained from a natural type separated in vivo from animals such as humans, cows, goats, pigs, mice, rabbits, hamsters, rats or guinea pigs, or obtained from transformed animal cells or microorganisms. It may be recombinant or a derivative thereof.
  • the method of obtaining from the natural form may be a method of separating the whole immunoglobulin from a human or animal living body, and then processing the protease. When treated with papain, it is cleaved into Fab and Fc, and when treated with pepsin, it is cleaved into pF'c and F (ab) 2.
  • Fc or pF'c may be separated by size-exclusion chromatography or the like.
  • the recombinant immunoglobulin Fc region obtained from a microorganism is an Fc region derived from human or mouse.
  • the immunoglobulin Fc region may be in a natural sugar chain, an increased sugar chain compared to the natural form, a reduced sugar chain or a sugar chain removed from the natural form.
  • Conventional methods such as chemical methods, enzymatic methods, and genetic engineering methods using microorganisms can be used to increase or decrease such immunoglobulin Fc sugar chains.
  • the immunoglobulin Fc region in which the sugar chain is removed from the Fc is significantly reduced in binding strength with the complement (c1q), and antibody-dependent cytotoxicity or complement-dependent cytotoxicity is reduced or eliminated, thereby not causing an unnecessary immune response in vivo. Do not.
  • a form more consistent with the original purpose as a carrier of the drug would be the immunoglobulin Fc region from which the sugar chains have been removed or unglycosylated.
  • “Deglycosylation” refers to an Fc region in which sugar is removed by an enzyme
  • Aglycosylation refers to an Fc region which is not produced and glycosylated in prokaryotes, and more specifically, in Escherichia coli. .
  • the immunoglobulin Fc region may be derived from humans or animals such as cattle, goats, pigs, mice, rabbits, hamsters, rats, guinea pigs, and the like, and may be derived from humans or mice.
  • the immunoglobulin Fc region of the present invention is IgG, IgA, IgD, IgE, IgM-derived Fc region, heavy chain constant region 2 (CH2), heavy chain constant region 3 (CH3), hinge, fragments thereof, or Hybrid Fc (combination), or combinations thereof.
  • the term "combination” refers to a polypeptide encoding a single-chain immunoglobulin Fc region, heavy chain constant region 2 (CH2) or heavy chain constant region 3 (CH3) when forming a dimer or multimer. Is meant to form a bond with single chain polypeptides of different origin. That is, it is possible to prepare dimers or multimers from two or more fragments selected from Fc region, heavy chain constant region 2 (CH2) or heavy chain constant region 3 (CH3) derived from IgG, IgA, IgM, IgD or IgE.
  • the "hybrid Fc" may be derived from a combination of human IgG subclasses or a combination of human IgD and IgG.
  • the hybrid Fc may include, for example, an IgD hinge region and a CH2 N-terminal region plus an IgG4 CH2 and CH3 region, for example, a hybrid Fc form disclosed in Korean Patent No. 0897938. May be used in the same manner, and is incorporated herein by reference.
  • the hybrid Fc when the hybrid Fc binds to a biologically active molecule, a polypeptide, or the like, it not only increases the serum half-life of the biologically active molecule, but also increases the expression level of the polypeptide when the nucleotide encoding the Fc-polypeptide fusion protein is expressed. It works.
  • the immunoglobulin Fc region is an Fc region derived from IgG, IgA, IgM, IgD or IgE, or heavy chain constant region 2 (CH2) and heavy chain constants derived from IgG, IgA, IgM, IgD or IgE.
  • Region 3 may be included, but is not limited thereto.
  • the immunoglobulin Fc region may be the IgG or IgM-derived Fc region that is most abundant in human blood, or may include the IgG or IgM-derived heavy chain constant region 2 (CH2) and heavy chain constant region 3 (CH3).
  • IgG-derived Fc region known to enhance half-life of a ligand binding protein, or may comprise heavy chain constant region 2 (CH2) and heavy chain constant region 3 (CH3) derived from said IgG, and another
  • it may be an Fc region derived from IgG1, IgG2, IgG3 or IgG4, or the heavy chain constant region 2 (CH2) and heavy chain constant region 3 (CH3) derived from the IgG1, IgG2, IgG3 or IgG4.
  • the immunoglobulin Fc region comprises heavy chain constant region 2 (CH2) and heavy chain constant region 3 (CH3) derived from human IgG1 represented by SEQ ID NO: 5, or derived from mouse IgG2 represented by SEQ ID NO: 6
  • the heavy chain constant region 2 (CH2) and heavy chain constant region 3 (CH3) of may include, but are not limited thereto (see Table 3 below).
  • Sequence Listing Sequence information SEQ ID NO: 5 LFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEKFSQVVSL SEQ ID NO: 6 IFPPKIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTAQTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKDLPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCVVVDDFMPEDIYVEVEKKNKKVKTKVHTAQTKN
  • the immunoglobulin Fc region may include a hinge region derived from IgG, IgA, IgM, IgD, IgE, or Abatacept, and as another example, IgG, IgD or Abatacept It may include a hinge region derived from, or may include, but is not limited to, a hinge region derived from IgG1, IgG2, IgG3, IgG4, IgD or Abatacept.
  • the immunoglobulin Fc region may comprise a hinge region derived from human IgG1 represented by SEQ ID NO: 7; A hinge region derived from mouse IgG2 represented by SEQ ID NO: 8; A hinge region derived from human IgD represented by SEQ ID NO: 9; And a hinge region of Abatacept represented by SEQ ID NO: 10 (see Table 4 below) to increase structural flexibility of the fusion protein to be finally produced and to improve productivity of the fusion protein. And stability can be significantly improved, but is not limited thereto.
  • the linker when the extracellular domain and the Fc region of the Lrig-1 protein are linked through a linker, the linker may be linked to the N-terminus, C-terminus or free radical of the Fc fragment, and Lrig-1 It may be linked to the N-terminus, C-terminus or free group of the extracellular domain of the protein. If the linker is a peptide linker, the linkage may occur at any site.
  • the linker may be linked to the C-terminus of the extracellular domain of the Lrig-1 protein and the N-terminus of the Fc region of the immunoglobulin, or the C-terminus and the Lrig of the Fc region of the immunoglobulin -1 may be linked to the N-terminus of the extracellular domain of the protein.
  • the "linker” reduces the interference effect between the extracellular domain of the Lrig-1 protein and the immunoglobulin Fc region in the fusion protein, thereby reducing the desired activity of the extracellular domain of the Lrig-1 protein in the target cell. It can increase.
  • the linker may include a sequence that may be cleaved by an enzyme that is overexpressed in a tissue or cell of a desired disease. When it can be cleaved by the overexpressed enzyme as described above it can effectively prevent the activity of the polypeptide is reduced due to the Fc portion.
  • the linker preferably has 1 to 100 amino acids, but is not limited thereto, and may be any peptide capable of separating the extracellular domain of the Lrig-1 protein from the immunoglobulin Fc region.
  • the amino acid sequence constituting the linker it is preferable to include glycine (G) and serine (S), or to include them repeatedly or in a random pattern.
  • the linker may be a peptide linker represented by SEQ ID NO: 11; And peptide linkers represented by SEQ ID NO: 12; By including at least one of the amino acid sequences of (GGGGS) N (N is an integer of 1 or more, preferably 1 to 20) (see Table 5 below), thereby improving the stability of the active substance in the cell. It can raise and productivity can be improved more.
  • a peptide linker consisting of 33 amino acids located at the 282th to 314th portions of the human albumin most present in the blood, more preferably 13th to 292 to 304th position It may be a peptide linker consisting of two amino acids, and this part is a part that is mostly exposed to the outside of the three-dimensional structure is a part that minimizes the possibility of inducing an immune response in the body. However, it is not limited thereto.
  • the linker when the linker and the Fc region are separately expressed and then bound to each other, the linker may be a crosslinking agent known in the art.
  • the crosslinking agent is, for example, 1,1-bis (diazoacetyl) -2-phenylethane (1,1-bis (diazoacetyl) -2-phenylethane), glutaraldehyde, 4-azidosalicyl N-hydroxysuccinimide esters, such as 4-azidosalicylic acid, 3,3'-dithiobis (succinimidylpropionate) Imidoesters, including disuccinimidyl esters, and bifunctional maleimides such as bis-N-maleimido-1,8-octane, but It is not limited.
  • a fusion protein is an extracellular domain of Lrig-1 protein represented by SEQ ID NO: 1; A hinge region represented by any one of SEQ ID NOs: 7 to 10; It may be a fusion protein comprising heavy chain constant region 2 (CH2) and heavy chain constant region 3 (CH3) derived from human IgG1 represented by SEQ ID NO: 5 (see Table 6 below).
  • the fusion proteins represented by SEQ ID NOs 13 to 16 of Table 6 may be encoded by the nucleic acid sequences represented by SEQ ID NOs 17 to 20 of Table 7 below (see Table 7 below).
  • Sequence Listing Sequence information SEQ ID NO: 13 AGPRAPCAAACTCAGDSLDCGGRGLAALPGDLPSWTRSLNLSYNKLSEIDPAGFEDLPNLQEVYLNNNELTAVPSLGAASSHVVSLFLQHNKIRSVEGSQLKAYLSLEVLDLSLNNITEVRNTCFPHGPPIKELNLAGNRIGTLELGAFDGLSRSLLTLRLSKNRITQLPVRAFKLPRLTQLDLNRNRIRLIEGLTFQGLNSLEVLKLQRNNISKLTDGAFWGLSKMHVLHLEYNSLVEVNSGSLYGLTALHQLHLSNNSIARIHRKGWSFCQKLHELVLSFNNLTRLDEESLAELSSLSVLRLSHNSISHIAEGAFKGLRSLRVLDLDLDHNEISGTIEDTSGAFSGLDSLSKLTLFGNKIKSVAKRAFSGLEGLEHLNLGGNAIRSVQFDAFVKMKNLKELHISSDSFLCDCQLKWLPPWLIGRMLQAFVTATC
  • a fusion protein is an extracellular domain of Lrig-1 protein represented by SEQ ID NO: 3; A hinge region represented by any one of SEQ ID NOs: 7 to 10; It may be a fusion protein comprising heavy chain constant region 2 (CH2) and heavy chain constant region 3 (CH3) derived from human IgG1 represented by SEQ ID NO: 5 (see Table 8 below).
  • the fusion proteins represented by SEQ ID NOs 21 to 24 in Table 8 may be encoded by nucleic acid sequences represented by SEQ ID NOs 25 to 28 in Table 9, respectively (see Table 9 below).
  • Sequence Listing Sequence information SEQ ID NO: 21 AQAGPRAPCAAACTCAGDSLDCSGRGLATLPRDLPSWTRSLNLSYNRLSEIDSAAFEDLTNLQEVYLNSNELTAIPSLGAASIGVVSLFLQHNKILSVDGSQLKSYLSLEVLDLSSNNITEIRSSCFPNGLRIRELNLASNRISILESGAFDGLSRSLLTLRLSKNRITQLPVKAFKLPRLTQLDLNRNRIRLIEGLTFQGLDSLEVLRLQRNNISRLTDGAFWGLSKMHVLHLEYNSLVEVNSGSLYGLTALHQLHLSNNSISRIQRDGWSFCQKLHELILSFNNLTRLDEESLAELSSLSILRLSHNAISHIAEGAFKGLKSLRVLDLDHNEISGTIEDTSGAFTGLDNLSKLTLFGNKIKSVAKRAFSGLESLEHLNLGENAIRSVQFDAFAKMKNLKELYISSESFLCDCQLKWLPPWLMGRMLQAFVTATCAHPE
  • a fusion protein is an extracellular domain of Lrig-1 protein represented by SEQ ID NO: 3; A hinge region represented by any one of SEQ ID NOs: 7 to 10; It may be a fusion protein comprising heavy chain constant region 2 (CH2) and heavy chain constant region 3 (CH3) derived from mouse IgG2 represented by SEQ ID NO: 6 (see Table 10 below).
  • the fusion proteins represented by SEQ ID NOs: 29 to 32 in Table 10 below may be encoded by nucleic acid sequences represented by SEQ ID NOs: 33 to 36 in Table 11, respectively (see Table 11 below).
  • Sequence Listing Sequence information SEQ ID NO: 29 AQAGPRAPCAAACTCAGDSLDCSGRGLATLPRDLPSWTRSLNLSYNRLSEIDSAAFEDLTNLQEVYLNSNELTAIPSLGAASIGVVSLFLQHNKILSVDGSQLKSYLSLEVLDLSSNNITEIRSSCFPNGLRIRELNLASNRISILESGAFDGLSRSLLTLRLSKNRITQLPVKAFKLPRLTQLDLNRNRIRLIEGLTFQGLDSLEVLRLQRNNISRLTDGAFWGLSKMHVLHLEYNSLVEVNSGSLYGLTALHQLHLSNNSISRIQRDGWSFCQKLHELILSFNNLTRLDEESLAELSSLSILRLSHNAISHIAEGAFKGLKSLRVLDLDHNEISGTIEDTSGAFTGLDNLSKLTLFGNKIKSVAKRAFSGLESLEHLNLGENAIRSVQFDAFAKMKNLKELYISSESFLCDCQLKWLPPWLMGRMLQAFVTATCAHPE
  • a fusion protein is an extracellular domain of Lrig-1 protein represented by SEQ ID NO: 1; A linker represented by SEQ ID NO: 11; A hinge region represented by any one of SEQ ID NOs: 7 to 10; It may be a fusion protein comprising heavy chain constant region 2 (CH2) and heavy chain constant region 3 (CH3) derived from human IgG1 represented by SEQ ID NO: 5 (see Table 12 below).
  • the fusion proteins represented by SEQ ID NOs 37 to 40 in Table 12 below may be encoded by nucleic acid sequences represented by SEQ ID NOs 41 to 44 in Table 13 below (see Table 13 below).
  • Sequence Listing Sequence information SEQ ID NO: 37 AGPRAPCAAACTCAGDSLDCGGRGLAALPGDLPSWTRSLNLSYNKLSEIDPAGFEDLPNLQEVYLNNNELTAVPSLGAASSHVVSLFLQHNKIRSVEGSQLKAYLSLEVLDLSLNNITEVRNTCFPHGPPIKELNLAGNRIGTLELGAFDGLSRSLLTLRLSKNRITQLPVRAFKLPRLTQLDLNRNRIRLIEGLTFQGLNSLEVLKLQRNNISKLTDGAFWGLSKMHVLHLEYNSLVEVNSGSLYGLTALHQLHLSNNSIARIHRKGWSFCQKLHELVLSFNNLTRLDEESLAELSSLSVLRLSHNSISHIAEGAFKGLRSLRVLDLDLDHNEISGTIEDTSGAFSGLDSLSKLTLFGNKIKSVAKRAFSGLEGLEHLNLGGNAIRSVQFDAFVKMKNLKELHISSDSFLCDCQLKWLPPWLIGRMLQAFVTATC
  • a fusion protein is an extracellular domain of Lrig-1 protein represented by SEQ ID NO: 3; A linker represented by SEQ ID NO: 11; A hinge region represented by any one of SEQ ID NOs: 7 to 10; It may be a fusion protein comprising heavy chain constant region 2 (CH2) and heavy chain constant region 3 (CH3) derived from human IgG1 represented by SEQ ID NO: 5 (see Table 14 below).
  • the fusion proteins represented by SEQ ID NOs: 45 to 48 in Table 14 below may be encoded by nucleic acid sequences represented by SEQ ID NOs: 49 to 52 in Table 15, respectively (see Table 15 below).
  • Sequence Listing Sequence information SEQ ID NO: 45 AQAGPRAPCAAACTCAGDSLDCSGRGLATLPRDLPSWTRSLNLSYNRLSEIDSAAFEDLTNLQEVYLNSNELTAIPSLGAASIGVVSLFLQHNKILSVDGSQLKSYLSLEVLDLSSNNITEIRSSCFPNGLRIRELNLASNRISILESGAFDGLSRSLLTLRLSKNRITQLPVKAFKLPRLTQLDLNRNRIRLIEGLTFQGLDSLEVLRLQRNNISRLTDGAFWGLSKMHVLHLEYNSLVEVNSGSLYGLTALHQLHLSNNSISRIQRDGWSFCQKLHELILSFNNLTRLDEESLAELSSLSILRLSHNAISHIAEGAFKGLKSLRVLDLDHNEISGTIEDTSGAFTGLDNLSKLTLFGNKIKSVAKRAFSGLESLEHLNLGENAIRSVQFDAFAKMKNLKELYISSESFLCDCQLKWLPPWLMGRMLQAFVTATCAHPE
  • a fusion protein is an extracellular domain of Lrig-1 protein represented by SEQ ID NO: 3; A linker represented by SEQ ID NO: 11; A hinge region represented by any one of SEQ ID NOs: 7 to 10; It may be a fusion protein comprising heavy chain constant region 2 (CH2) and heavy chain constant region 3 (CH3) derived from mouse IgG2 represented by SEQ ID NO: 6 (see Table 16 below).
  • the fusion proteins represented by SEQ ID NOs 53 to 56 in Table 16 below may be encoded by nucleic acid sequences represented by SEQ ID NOs 57 to 60 in Table 17 below (see Table 17 below).
  • Sequence Listing Sequence information SEQ ID NO: 53 AQAGPRAPCAAACTCAGDSLDCSGRGLATLPRDLPSWTRSLNLSYNRLSEIDSAAFEDLTNLQEVYLNSNELTAIPSLGAASIGVVSLFLQHNKILSVDGSQLKSYLSLEVLDLSSNNITEIRSSCFPNGLRIRELNLASNRISILESGAFDGLSRSLLTLRLSKNRITQLPVKAFKLPRLTQLDLNRNRIRLIEGLTFQGLDSLEVLRLQRNNISRLTDGAFWGLSKMHVLHLEYNSLVEVNSGSLYGLTALHQLHLSNNSISRIQRDGWSFCQKLHELILSFNNLTRLDEESLAELSSLSILRLSHNAISHIAEGAFKGLKSLRVLDLDHNEISGTIEDTSGAFTGLDNLSKLTLFGNKIKSVAKRAFSGLESLEHLNLGENAIRSVQFDAFAKMKNLKELYISSESFLCDCQLKWLPPWLMGRMLQAFVTATCAHPE
  • a fusion protein is an extracellular domain of Lrig-1 protein represented by SEQ ID NO: 1; A linker represented by SEQ ID NO: 12; A linker represented by SEQ ID NO: 11; A hinge region represented by any one of SEQ ID NOs: 7 to 10; It may be a fusion protein comprising heavy chain constant region 2 (CH2) and heavy chain constant region 3 (CH3) derived from human IgG1 represented by SEQ ID NO: 5 (see Table 18 below).
  • the fusion protein represented by SEQ ID NOs: 61 to 64 in Table 18 below may be encoded by the nucleic acid sequence represented by SEQ ID NOs: 65 to 68 in Table 19 below (see Table 19 below).
  • a fusion protein is an extracellular domain of Lrig-1 protein represented by SEQ ID NO: 3; A linker represented by SEQ ID NO: 12; A linker represented by SEQ ID NO: 11; A hinge region represented by any one of SEQ ID NOs: 7 to 10; It may be a fusion protein comprising heavy chain constant region 2 (CH2) and heavy chain constant region 3 (CH3) derived from human IgG1 represented by SEQ ID NO: 5 (see Table 20 below).
  • the fusion proteins represented by SEQ ID NOs: 69 to 72 in Table 20 below may be encoded by nucleic acid sequences represented by SEQ ID NOs: 73 to 76 in Table 21 below (see Table 21 below).
  • a fusion protein is an extracellular domain of Lrig-1 protein represented by SEQ ID NO: 3; A linker represented by SEQ ID NO: 12; A linker represented by SEQ ID NO: 11; A hinge region represented by any one of SEQ ID NOs: 7 to 10; It may be a fusion protein comprising heavy chain constant region 2 (CH2) and heavy chain constant region 3 (CH3) derived from mouse IgG2 represented by SEQ ID NO: 6 (see Table 22 below).
  • the fusion protein represented by SEQ ID NOs 77 to 80 of Table 22 below may be encoded by the nucleic acid sequence represented by SEQ ID NOs 81 to 84 of Table 23 below (see Table 23 below).
  • the fusion protein provided in the present invention interacts with a ligand for Lrig-1 protein present in effector T cells, thereby regulating T cells containing Lrig-1 protein on the surface. Inhibiting the interaction between Treg cells and effector T cells can inhibit the activity of regulatory T cells and maintain or elevate the activity of effector T cells, thereby effectively inhibiting the growth of solid cancer cells, particularly among cancer cells.
  • nucleic acid molecule encoding the fusion protein provided by the present invention is provided.
  • Nucleic acid molecules of the present invention include all nucleic acid molecules in which the amino acid sequence of the fusion protein provided herein is translated into a polynucleotide sequence as known to those skilled in the art. Therefore, various polynucleotide sequences can be prepared by an open reading frame (ORF), all of which are also included in the nucleic acid molecules of the present invention.
  • ORF open reading frame
  • the nucleic acid molecule is SEQ ID NO: 17 to 20, 25 to 28, 33 to 36, 41 to 44, 49 to 52, 57 to 60, 65 to 68, 73 to 76 and 81 to 84 It may be displayed as one, but is not limited thereto.
  • an expression vector into which the isolated nucleic acid molecule provided in the present invention is inserted is provided.
  • the "vector” is the nucleic acid molecule capable of transporting another nucleic acid to which a nucleic acid molecule is linked.
  • a vector which refers to circular double stranded DNA into which additional DNA segments can be ligated.
  • a phage vector Another type of vector is a viral vector, where additional DNA segments can be ligated into the viral genome.
  • Some vectors are capable of autonomous replication in the host cell into which they are introduced (eg, bacterial vectors are episomal mammalian vectors of bacterial replication origin).
  • vectors eg, non-episomal mammalian vectors
  • Other vectors can enter the host cell and integrate into the genome of the host cell, thereby replicating with the host genome.
  • some vectors can direct the expression of the genes to which they are linked in a working dimension.
  • Such vectors are referred to herein as “recombinant expression vectors” or simply "expression vectors.”
  • expression vectors of utility in recombinant DNA techniques are often in the form of plasmids.
  • plasmid and vector may be used interchangeably because the plasmid is the most commonly used form of the vector.
  • the expression vector in the present invention include commercially widely used pCDNA vectors, F, R1, RP1, Col, pBR322, ToL, Ti vectors; Cosmid; Phages such as lambda, lambdoid, M13, Mu, p1 P22, Q ⁇ , T-even, T2, T3, T7; It can be selected from the group consisting of plant viruses, but is not limited thereto. All expression vectors known to those skilled in the art as expression vectors can be used in the present invention, and the selection of the expression vector depends on the nature of the host cell of interest.
  • the introduction of the vector into the host cell may be performed by calcium phosphate transfection, viral infection, DEAE-dextran controlled transfection, lipofectamine transfection or electroporation, but is not limited thereto.
  • An introduction method suitable for the expression vector and the host cell can be selected and used.
  • the vector contains one or more selection markers, but is not limited thereto, and may be selected depending on whether the product is produced using a vector that does not include the selection marker.
  • the selection of the selection marker is selected by the host cell of interest, which uses methods already known to those skilled in the art and the present invention is not so limited.
  • tag sequences can be inserted and fused to an expression vector.
  • the tag may include, but is not limited to, a hexa-histidine tag, a hemagglutinin tag, a myc tag, or a flag tag. Any tag that facilitates purification known to those skilled in the art may be used in the present invention.
  • a host cell line transfected with the expression vector provided in the present invention.
  • the "host cell” includes individual cells or cell cultures that may or may have been recipients of the vector (s) for incorporation of the polypeptide insert.
  • Host cells include the progeny of a single host cell, which may not necessarily be exactly the same (in morphological or genomic DNA complement) as the original parent cell because of natural, accidental or intentional mutations.
  • Host cells include cells transfected in vivo with the polypeptide (s) herein.
  • the host cell may include cells of mammalian, plant, insect, fungal or cellular origin, for example, bacterial cells such as E. coli, Streptomyces, Salmonella typhimurium; Fungal cells such as yeast cells and peach pastoris; Insect cells such as Drozophila and Spodoptera Sf9 cells; Chinese hamster ovary cells (CHO), SP2 / 0 (mouse myeloma), human lymphoblastoid, COS, NSO (mouse myeloma), 293T, bow melanoma cells, HT-1080, BHK (Baby hamster kidney cells, Baby Hamster Kidney cells), animal cells of HEK (Human Embryonic Kidney cells) or PERC.6 (human retinal cells); Or it may be a plant cell, but is not limited thereto, any cell that can be used as a host cell line known to those skilled in the art is available.
  • bacterial cells such as E. coli, Streptomy
  • a pharmaceutical composition for preventing or treating cancer comprising the fusion protein provided by the present invention as an active ingredient is provided.
  • the cancer to be prevented, improved or treated may be a solid tumor composed of agglomerates caused by abnormal growth of cells in a solid organ, and according to the site of the solid organ, stomach cancer, liver cancer, Glioblastoma, ovarian cancer, colon cancer, head and neck cancer, bladder cancer, renal cell cancer, breast cancer, metastatic cancer, prostate cancer, pancreatic cancer, melanoma or lung cancer, and the like, preferably melanoma or colorectal cancer, but is not limited thereto. It is not.
  • prophylaxis may be used without limitation any action to block the symptoms of the disease, or to suppress or delay the symptoms using the pharmaceutical composition of the present invention.
  • treatment may include without limitation any action that improves or benefits the symptoms of the disease using the pharmaceutical composition of the present invention.
  • the pharmaceutical composition may be characterized in that the capsule, tablets, granules, injections, ointments, powder or beverage form, the pharmaceutical composition may be characterized in that it is intended for humans.
  • the pharmaceutical composition is not limited thereto, but may be used in the form of oral dosage forms, external preparations, suppositories, and sterile injectable solutions, such as powders, granules, capsules, tablets, and aqueous suspensions, respectively, according to conventional methods.
  • the pharmaceutical composition of the present invention may comprise a pharmaceutically acceptable carrier.
  • Pharmaceutically acceptable carriers can be used as oral administration binders, suspending agents, disintegrants, excipients, solubilizers, dispersants, stabilizers, suspending agents, pigments, fragrances, etc.
  • buffers, preservatives, analgesic Topical agents, solubilizers, isotonic agents, stabilizers and the like can be mixed and used, and for topical administration, bases, excipients, lubricants, preservatives and the like can be used.
  • the formulation of the pharmaceutical composition of the present invention can be prepared in various ways by mixing with a pharmaceutically acceptable carrier as described above.
  • oral administration may be in the form of tablets, troches, capsules, elixirs, suspensions, syrups, wafers, and the like, in the case of injections, in unit dosage ampoules or multiple dosage forms. have. And other solutions, suspensions, tablets, capsules, sustained release preparations and the like.
  • suitable carriers, excipients and diluents suitable for formulation include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, malditol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, Cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate or mineral oil and the like can be used.
  • fillers, anti-coagulants, lubricants, wetting agents, fragrances, emulsifiers, preservatives and the like may further be included.
  • the route of administration of the pharmaceutical composition in the present invention is not limited to these, oral, intravenous, intramuscular, intraarterial, intramedullary, intradural, intracardiac, transdermal, subcutaneous, intraperitoneal, intranasal, intestinal, topical, Sublingual or rectal. Oral or parenteral release is preferred.
  • parenteral includes subcutaneous, intradermal, intravenous, intramuscular, intraarticular, intramuscular, intrasternal, intradural, intralesional and intracranial injection or infusion techniques.
  • the pharmaceutical compositions of the invention may also be administered in the form of suppositories for rectal administration.
  • the pharmaceutical composition of the present invention depends on a number of factors, including the activity, age, weight, general health, sex, formulation, time of administration, route of administration, rate of release, drug combination and severity of the particular disease to be prevented or treated, of the specific compound employed.
  • the dosage of the pharmaceutical composition may vary depending on the patient's condition, weight, degree of disease, drug form, route of administration, and duration, and may be appropriately selected by those skilled in the art, and 0.0001 to 50 mg / kg per day. Or 0.001 to 50 mg / kg. Administration may be administered once a day or may be divided several times. The dosage does not limit the scope of the invention in any aspect.
  • the pharmaceutical composition according to the present invention may be formulated as pills, dragees, capsules, solutions, gels, syrups, slurries, suspensions.
  • a method for preventing or treating cancer comprising administering to a subject a fusion protein or a composition comprising the same according to the present invention.
  • the fusion protein of the present invention interacts with ligands for Lrig-1 protein present in effector T cells, thereby regulating T cells and effector T cells containing Lrig-1 protein on the surface.
  • the activity of regulatory T cells can be inhibited and the effector T cells can be maintained or elevated to effectively inhibit the growth of solid cancer cells, particularly among cancer cells.
  • the "individual” is a subject suspected of developing cancer
  • the suspected subject of cancer refers to a mammal including a mouse, a livestock, and the like, including a human having or may have the disease
  • Individuals treatable with the fusion protein of the invention or the composition comprising the same are included without limitation.
  • the methods of the present invention may comprise administering a fusion protein or a composition comprising the same in a pharmaceutically effective amount.
  • Suitable total daily doses may be determined by the treating physician within the scope of good medical judgment and may be administered once or in divided doses.
  • the specific therapeutically effective amount for a particular patient is determined by the specific composition, including the type and extent of the reaction to be achieved, whether or not other agents are used in some cases, the age, weight, general health of the patient, It is desirable to apply differently depending on various factors and similar factors well known in the medical field, including sex and diet, time of administration, route of administration and rate of composition, duration of treatment, drugs used with or co-specific with the specific composition.
  • the method for preventing or treating cancer may be a combination therapy further comprising administering a compound or substance having a therapeutic activity against one or more cancer diseases.
  • the "combination” is to be understood to denote simultaneous, separate or sequential administration. If the administration is sequential or separate, the interval of administration of the secondary components should be such that the beneficial effect of the combination is not lost.
  • the dosage of the fusion protein may be about 0.0001 ⁇ g to 500 mg per kg of patient's body weight, but is not limited thereto.
  • the fusion protein provided in the present invention interacts with a ligand for Lrig-1 protein present in effector T cells, thereby regulating T cells and effectors containing Lrig-1 protein on the surface.
  • a ligand for Lrig-1 protein present in effector T cells By inhibiting the interaction between T cells, the activity of regulatory T cells can be inhibited and the effector T cells can be maintained or elevated to effectively inhibit the growth of solid cancer cells, particularly among cancer cells.
  • Figure 1 shows the structure of the Lrig-1 protein according to an embodiment of the present invention.
  • FIG. 2 shows the structure of the Lrig-1 protein according to an embodiment of the present invention.
  • Figure 3 shows the results of predicting the epitope of the antigen of the Lrig-1 protein according to an embodiment of the present invention.
  • Figure 4 shows the results of predicting the epitope of the antigen of the Lrig-1 protein according to an embodiment of the present invention.
  • Figure 5 shows the expression level of Lrig-1 mRNA according to an embodiment of the present invention.
  • Figure 6 shows the expression level of Lrig-1 mRNA according to an embodiment of the present invention.
  • Figure 7 shows the expression level of Lrig-1 mRNA according to an embodiment of the present invention.
  • Figure 8 shows the expression level of Lrig-1, Lrig-2 and Lrig-3 mRNA according to an embodiment of the present invention.
  • Figure 9 shows the results of comparing the expression level of Lrig-1 protein in regulatory T cells and non-regulated T cells according to an embodiment of the present invention.
  • Figure 10 shows the expression of Lrig-1 protein on the surface of regulatory T cells according to an embodiment of the present invention.
  • Figure 11 shows the effect of inhibiting the inhibitory ability of regulatory T cells to effector T cells of the fusion protein according to an embodiment of the present invention.
  • Figure 12 shows a subset of T cells in which there is a ligand recognized by the fusion protein according to one embodiment of the invention.
  • Figure 13 shows the design of a cancer treatment experiment using a fusion protein according to an embodiment of the present invention.
  • Figure 14 shows the results of analyzing the cancer treatment effect using a fusion protein according to an embodiment of the present invention.
  • Figure 15 shows the results of analyzing the cancer treatment effect using a fusion protein according to an embodiment of the present invention.
  • the present invention relates to a fusion protein comprising an extracellular domain and an immunoglobulin Fc region of the leucine-rich and immunoglobulin-like domains 1 (Lrig-1) protein.
  • the immunoglobulin Fc region is an Fc region derived from IgG, IgA, IgM, IgD or IgE, or heavy chain constant region 2 (CH2) and heavy chain constants derived from IgG, IgA, IgM, IgD or IgE.
  • Region 3 may be included, but is not limited thereto.
  • the immunoglobulin Fc region may include a hinge region derived from IgG, IgA, IgM, IgD, IgE, or Abatacept, but is not limited thereto.
  • the extracellular domain of the Lrig-1 protein may be linked to the N-terminus or C-terminus of the immunoglobulin Fc region through a linker, but is not limited thereto.
  • the present invention relates to a pharmaceutical composition for preventing or treating cancer, comprising the fusion protein of the present invention as an active ingredient.
  • the fusion protein provided in the present invention interacts with a ligand for Lrig-1 protein present in effector T cells, thereby regulating T cells and effectors containing Lrig-1 protein on the surface.
  • a ligand for Lrig-1 protein present in effector T cells By inhibiting the interaction between T cells, the activity of regulatory T cells can be inhibited and the effector T cells can be maintained or elevated to effectively inhibit the growth of solid cancer cells, particularly among cancer cells.
  • T cells In order to confirm that Lrig-1 protein is expressed only in regulatory T cells (Treg), subsets of T cells, Th0, Th1, Th2, Th17 and iTreg, were prepared.
  • the iTreg refers to cells which artificially induced differentiation in a medium containing the following composition, unlike nTreg, which is naturally isolated.
  • T cells were first isolated from na ⁇ ve T cells obtained from the spleen of the rat, and then RPMI1640 containing 10% fetal bovine serum (FBS; hyclone, logan, UT) (Invitrogen Gibco, Grand Island, NY). The components of Table 24 were further included in the nutrient medium, and differentiation was induced to each cell through 72 hours of incubation in a 37 ° C., 5% CO 2 incubator.
  • FBS fetal bovine serum
  • the three-dimensional conformation of the extracellular domain of Lrig-1 protein was predicted to produce a fusion protein including the extracellular domain of Lrig-1 protein, which is a surface protein of regulatory T cells.
  • LRR1 to LRR15 existed in the Lrig-LRR domain (amino acid sequence Nos. 41 to 494) in the extracellular domain of Lrig-1 protein.
  • LRR domains consisted of 23 to 27 amino acids, with 3 to 5 leucine present.
  • the prediction of the nucleotide sequence was performed using Ellipro server (http://tools.iedb.org/ellipro/), which is an epitope prediction software based on the structure of the Lrig-1 protein.
  • the Ellipro search engine corresponds to a search engine known to have the highest reliability among algorithms for predicting existing antigenic determinants.
  • Example 2 After entering the extracellular domain analyzed in Example 1 into the epitope predictor software, the predicted contiguous or discontinuous amino acid sequences of the predicted epitope are shown in FIGS. 3 and 4.
  • Lrig-1 protein could act as a biomarker specific for regulatory T cells.
  • CD4 + T cells were isolated from the spleen of mice using magnet-activated cell sorting (MACS) through CD4 beads. Thereafter, regulatory T (CD4 + CD25 + T) cells and non-regulated T (CD4 + CD25 ⁇ T) cells were separated using a fluorescent activated cell sorter (FACS) using a CD25 antibody.
  • FACS fluorescent activated cell sorter
  • Each cell and the cells differentiated in Preparation Example 1 extracted mRNA using Trizol, and genomic RNA removed gDNA by a protocol provided by a company using gDNA extraction kit (Qiagen). . gDNA removed mRNA was synthesized into cDNA through the BDsprint cDNA Synthesis Kit (Clonetech).
  • the real-time polymerase chain reaction was carried out in 40 cycles of 3 minutes at 95 °C, 15 seconds at 61 °C, 30 seconds at 72 °C by the protocol provided by the manufacturer using SYBR Green (Molecular Probes), Table 25 It was performed using a primer, relative gene expression was calculated using the ⁇ CT method, and normalized using HPRT, the results are shown in Figures 5 to 8.
  • Lrig-1 expression was the highest among the Lrig-1, Lrig-2 and Lrig-3 corresponding to the Lrig family.
  • Lrig-1 protein according to the present invention is specifically expressed in regulatory T cells, particularly naturally occurring regulatory T cells.
  • Lrig-1 protein expressed from Lrig-1 mRNA was specifically expressed only in regulatory T cells.
  • a magnet-activated cell sorter (magnet-activated) from a mouse's spleen to CD4 beads using FOXP3-RFP-Knock-in mice incorporating a red fluorescence protein (RFP) to the FOXP3 promoter, a regulatory T cell specific transcription factor CD4 + T cells were isolated using cell sorting (MACS). Then, using a RFP protein, regulatory T cells (CD4 + RFP + T cells) and non-regulated T cells (CD4 + RFP - T cells) were obtained by fluorescence activated cell sorter (FACS). Each of the cells was purchased Lrig-1 antibody and negative control wasotype (isotype) staining to measure the expression level of Lrig-1 with a fluorescent active cell sorter, the results are shown in Figure 9.
  • RFP red fluorescence protein
  • the non-regulated T cells indicated by dotted lines showed almost the same expression level of Lrig-1 as the negative control, but there were a large number of cells with high expression levels of Lrig-1 in the case of regulatory T cells. .
  • Lrig-1 protein according to the present invention is specifically expressed in regulatory T cells.
  • Lrig-1 protein In order for Lrig-1 protein to be a target of cell therapy, it must be expressed on the surface of regulatory T cells to more effectively target the treatment. Therefore, it was confirmed whether Lrig-1 protein was expressed on the surface.
  • Each differentiated T cell subtype of Preparation Example 1 was stained with anti-CD4-APC and anti-Lrig-1-PE antibodies and surfaced to each cell using a Fluorescence-Activated Cell Sorter (FACS). The expression level of Lrig-1 at was measured, and the results are shown in FIG.
  • Lrig-1 is expressed in an amount of 0.77 to 15.3 in activated T cells, Th1 cells, Th2 cells, Th17 cells, and Naive T cells, whereas differentiation. was highly expressed as 83.9 in T-induced T cells (iTreg).
  • the Lrig-1 protein according to the present invention is not only specifically expressed in regulatory T cells (Treg) cells, but also particularly expressed on the surface of the regulatory T cells.
  • each nucleic acid sequence encoding each fusion protein in Table 26 was synthesized. NheI and EcoRI restriction enzyme sequences were added to the 5 'and 3' ends of the nucleic acid sequence, respectively, followed by a Kozak's sequence (GCCACC) and a start codon for protein translation. Mouse IgG kappa light chain signal peptide (ATGGAAACCGATACTCTGCTGCTGTGGGTGCTGCTGCTGTGGGTGCCAGGCTCTACCGGG) was inserted to allow the protein to be secreted out of the cells.
  • nucleic acid sequence encoding each of the fusion proteins of Table 26 the extracellular domain of the human-derived Lrig-1 protein; Optionally a linker; Hinge area; A stop codon was inserted after the nucleic acid sequence encoding heavy chain constant region 2 (CH2) and heavy chain constant region 3 (CH3) derived from human IgG1.
  • the nucleic acid sequence encoding the fusion protein of the present invention was cloned into a pcDNA3.1 (+) expression vector using two restriction enzyme sequences, NheI and EcoRI.
  • 293F cells were transformed using polyethyleneimine (Polyethylenimine) and the expression vector prepared in 1. was incubated for 6 days at 37 °C and 8% CO 2 conditions. The culture supernatant was filtered and poured into Protein A resin and washed with 1X PBS. The solution was eluted with a 0.1 M glycine solution at pH 3.5 and then neutralized by adding 1 M TRIS solution at pH 9.0 to the resulting solution. The solution was then dialyzed into PBS solution and concentrated.
  • polyethyleneimine Polyethylenimine
  • the fusion protein represented by SEQ ID NO: 21 according to the present invention prepared in Preparation Example 5 (manufactured using a nucleic acid sequence represented by SEQ ID NO: 25) binds to a ligand for Lrig-1 protein, and The following experiment was performed to confirm whether finally inhibiting the proliferation inhibitory effect on the effector T cells of regulatory T cells by inhibiting the interaction between regulatory T cells.
  • the fusion protein of Preparation Example 5 was added under conditions of coculture of regulatory T cells and effector T cells to confirm the change of the proliferation inhibitory ability of the regulatory T cells on the effector T cells. The results are shown in FIG.
  • the treatment of the fusion protein according to the present invention was confirmed that the effect of suppressing the proliferation of regulatory T cells to effector T cells.
  • the fusion protein according to the present invention interacts with the ligand for the Lrig-1 protein, thereby inhibiting the interaction between the regulatory T cell containing the Lrig-1 protein and the ligand, thereby activating regulatory T cells.
  • the activity of effector T cells was maintained or elevated.
  • the fusion protein represented by SEQ ID NO: 21 according to the present invention prepared in Preparation Example 5 may recognize the Lrig-1 ligand.
  • activated T cells, Th1 cells, and Th2 cells from naive T cells which are considered targets of regulatory T cells.
  • these cells were stained with the fusion protein (primary antibody) and anti-human-PE antibody (secondary antibody) of Preparation Example 5 above.
  • the expression level of the fusion protein at each cell surface was measured using a fluorescence-activated cell sorter (FACS), and the results are shown in FIG. 12.
  • the fusion protein according to the present invention hardly stained antigen on the surface of na ⁇ ve T cells (0.71%), and the surface of activated T cells, Th1 cells, Th2 cells, and Th17 cells. Antigens in stained more than 96%.
  • the ligand of Lrig-1 was found to be a surface protein induced by the stimulation of the T cell receptor (receptor).
  • the treatment of the fusion protein according to the present invention was found to significantly reduce the size of melanoma tumors compared to the negative control.
  • the fusion protein produced using the nucleic acid sequence represented by SEQ ID NO: 82
  • SEQ ID NO: 78 represented by SEQ ID NO: 78 according to the present invention prepared in Preparation Example 34 for solid cancer
  • CT-26 colorectal cancer cells After subcutaneous injection in the amount of 3 ⁇ 10 5 cells in mice, etc., the fusion protein of Preparation 34 was injected intraperitoneally on the 4th, 8th and 12th days. The change in the volume of the tumor over time after the colorectal cancer cell transplantation was measured and the results are shown in FIG. 15.
  • the fusion protein comprising the extracellular domain and immunoglobulin Fc region of the Lrig-1 protein according to the present invention inhibits the activity of regulatory T cells and inhibits the effector T effector by inhibiting the interaction between regulatory T cells and effector T cells. It can be seen that the activity of the cells can be maintained or raised to effectively inhibit the growth of solid cancer cells, particularly among cancer cells.
  • the present invention relates to a novel fusion protein comprising an extracellular domain of an Lrig-1 protein and an immunoglobulin Fc region, and use for the prevention or treatment of cancer using the same.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PCT/KR2019/005096 2018-04-26 2019-04-26 신규한 융합 단백질 및 이를 포함하는 암의 예방 또는 치료용 약학적 조성물 Ceased WO2019209078A1 (ko)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP19793399.7A EP3792276A4 (en) 2018-04-26 2019-04-26 NOVEL FUSION PROTEIN AND PHARMACEUTICAL COMPOSITION TO PREVENT OR TREAT CANCER THEREOF
CN201980028463.XA CN112041333B (zh) 2018-04-26 2019-04-26 新型融合蛋白和用于预防或治疗癌症的包含该融合蛋白的药物组合物
JP2020559369A JP7485368B2 (ja) 2018-04-26 2019-04-26 新規な融合タンパク質およびこれを含む癌の予防または治療用薬学的組成物
US17/050,816 US11820801B2 (en) 2018-04-26 2019-04-26 Fusion protein, and pharmaceutical composition for preventing or treating cancer, containing same

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2018-0048343 2018-04-26
KR20180048343 2018-04-26

Publications (1)

Publication Number Publication Date
WO2019209078A1 true WO2019209078A1 (ko) 2019-10-31

Family

ID=68293649

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2019/005096 Ceased WO2019209078A1 (ko) 2018-04-26 2019-04-26 신규한 융합 단백질 및 이를 포함하는 암의 예방 또는 치료용 약학적 조성물

Country Status (6)

Country Link
US (1) US11820801B2 (https=)
EP (1) EP3792276A4 (https=)
JP (1) JP7485368B2 (https=)
KR (3) KR102194644B1 (https=)
CN (1) CN112041333B (https=)
WO (1) WO2019209078A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111285936A (zh) * 2020-03-11 2020-06-16 北京双赢科创生物科技有限公司 靶向肿瘤的酸性敏感纳米肽段及其应用
JP2023500248A (ja) * 2019-11-08 2023-01-05 グッド ティー セルズ、 インコーポレイテッド 制御性ｔ細胞表面抗原のエピトープおよびこれに特異的に結合する抗体

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210347849A1 (en) * 2018-07-24 2021-11-11 Good T Cells, Inc. Composition for Preventing or Treating Immune-Related Diseases
CN113811330A (zh) * 2019-03-20 2021-12-17 古德T细胞有限公司 预防或治疗脑和神经系统疾病的组合物
KR20250036703A (ko) * 2023-09-06 2025-03-14 주식회사 굳티셀 친화도 성숙이 이루어진 신규 항체

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
WO1996032478A1 (en) 1995-04-14 1996-10-17 Genentech, Inc. Altered polypeptides with increased half-life
US5624821A (en) 1987-03-18 1997-04-29 Scotgen Biopharmaceuticals Incorporated Antibodies with altered effector functions
WO1997034631A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
US6086875A (en) 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
KR20060124656A (ko) * 2003-12-31 2006-12-05 메르크 파텐트 게엠베하 개선된 약물동태를 가지는 Ｆｃ-에리스로포이에틴 융합단백질
KR100888022B1 (ko) * 2006-12-21 2009-03-09 재단법인 목암생명공학연구소 면역글로불린 Ｆｃ와 인간 아포리포단백질（ａ）크링글절편의 융합단백질 ＬＫ8­Ｆｃ
KR100897938B1 (ko) 2007-05-30 2009-05-18 주식회사 제넥신 면역글로불린 융합 단백질
KR101530065B1 (ko) * 2010-06-11 2015-06-18 베이징 동팡 바이오테크 컴퍼니 리미티드 엑센딘-4 및 이의 유사체의 융합 단백질, 제조방법 및 이의 용도
KR101639015B1 (ko) * 2013-07-30 2016-07-14 연세대학교 산학협력단 삭사틸린―Ｆｃ 융합 단백질 및 이의 용도

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007013671A2 (en) * 2005-07-27 2007-02-01 Oncotherapy Science, Inc. Method of diagnosing esophageal cancer
US7846445B2 (en) 2005-09-27 2010-12-07 Amunix Operating, Inc. Methods for production of unstructured recombinant polymers and uses thereof
US8933197B2 (en) * 2007-08-15 2015-01-13 Amunix Operating Inc. Compositions comprising modified biologically active polypeptides
KR101847523B1 (ko) 2011-01-24 2018-05-28 연세대학교 산학협력단 조절자 Ｔ 세포에 특이적으로 존재하는 새로운 표면단백질 Ｌｒｉｇ-1의 용도
RS61391B1 (sr) 2012-06-08 2021-02-26 Alkermes Pharma Ireland Ltd Ligandi modifikovani primenom cirkularnog permutiranja kao agonisti i antagonisti
EP3456734B1 (en) 2012-10-04 2022-01-05 Research Development Foundation Serine protease molecules and therapies
US20210347849A1 (en) 2018-07-24 2021-11-11 Good T Cells, Inc. Composition for Preventing or Treating Immune-Related Diseases

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5624821A (en) 1987-03-18 1997-04-29 Scotgen Biopharmaceuticals Incorporated Antibodies with altered effector functions
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
US6086875A (en) 1995-01-17 2000-07-11 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of immunogens
WO1996032478A1 (en) 1995-04-14 1996-10-17 Genentech, Inc. Altered polypeptides with increased half-life
WO1997034631A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
KR20060124656A (ko) * 2003-12-31 2006-12-05 메르크 파텐트 게엠베하 개선된 약물동태를 가지는 Ｆｃ-에리스로포이에틴 융합단백질
KR100888022B1 (ko) * 2006-12-21 2009-03-09 재단법인 목암생명공학연구소 면역글로불린 Ｆｃ와 인간 아포리포단백질（ａ）크링글절편의 융합단백질 ＬＫ8­Ｆｃ
KR100897938B1 (ko) 2007-05-30 2009-05-18 주식회사 제넥신 면역글로불린 융합 단백질
KR101530065B1 (ko) * 2010-06-11 2015-06-18 베이징 동팡 바이오테크 컴퍼니 리미티드 엑센딘-4 및 이의 유사체의 융합 단백질, 제조방법 및 이의 용도
KR101639015B1 (ko) * 2013-07-30 2016-07-14 연세대학교 산학협력단 삭사틸린―Ｆｃ 융합 단백질 및 이의 용도

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CHANG, L. ET AL.: "Restoration of LRIG1 suppresses bladder cancer cell growth by directly targeting EGFR activity", JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, vol. 32, no. 101, 2013, pages 1 - 9, XP021173759, DOI: 10.1186/1756-9966-32-101 *
H. NEURATHR. L. HILL: "The Proteins", 1979, ACADEMIC PRESS
JANEWAY ET AL.: "Immunobiology", 2001, GARLAND PUBLISHING
JOHANSSON, M. ET AL.: "The soluble form of the tumor suppressor Lrig1 potently inhibits in vivo glioma growth irrespective of EGF receptor status", NEURO-ONCOLOGY, vol. 15, no. 9, 2013, pages 1200 - 1211, XP055239540, DOI: 10.1093/neuonc/not054 *
OSBORN BL ET AL., U.S. FOOD AND DRUG ADMINISTRATION, 2002

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023500248A (ja) * 2019-11-08 2023-01-05 グッド ティー セルズ、 インコーポレイテッド 制御性ｔ細胞表面抗原のエピトープおよびこれに特異的に結合する抗体
CN111285936A (zh) * 2020-03-11 2020-06-16 北京双赢科创生物科技有限公司 靶向肿瘤的酸性敏感纳米肽段及其应用

Also Published As

Publication number Publication date
EP3792276A4 (en) 2022-02-16
KR20230146491A (ko) 2023-10-19
US20210130422A1 (en) 2021-05-06
JP2021521817A (ja) 2021-08-30
US11820801B2 (en) 2023-11-21
KR102754984B1 (ko) 2025-01-21
JP7485368B2 (ja) 2024-05-16
CN112041333B (zh) 2024-06-28
CN112041333A (zh) 2020-12-04
KR20200144524A (ko) 2020-12-29
KR102194644B1 (ko) 2020-12-24
KR20190124665A (ko) 2019-11-05
EP3792276A1 (en) 2021-03-17

Similar Documents

Publication Publication Date Title
WO2019209078A1 (ko) 신규한 융합 단백질 및 이를 포함하는 암의 예방 또는 치료용 약학적 조성물
WO2020022782A1 (ko) 면역 관련 질환의 예방 또는 치료용 조성물
WO2019155408A1 (en) Anti-pd-1/anti-her2 natural antibody structural heterodimeric bispecific antibody and method of preparing same
WO2019004799A1 (ko) Vegf-grab 단백질과 약물의 결합체 및 이의 용도
WO2017030370A1 (ko) 항-코티닌 항체가 연결된 키메라 항체 수용체 및 이의 용도
WO2021091359A1 (ko) 조절 t 세포 표면 항원의 에피토프 및 이에 특이적으로 결합하는 항체
WO2022231032A1 (ko) 항-cntn4 특이적 항체 및 그의 용도
WO2021235697A1 (ko) Cd22에 특이적인 항체 및 이의 용도
WO2019216675A1 (ko) 조절 t 세포 표면 항원의 에피토프 및 이에 특이적으로 결합하는 항체
JP2021521817A5 (https=)
WO2021154046A1 (ko) pH-감응성 FC 변이체
WO2020004937A1 (ko) 항-bcma 항체-약물 접합체 및 그 용도
WO2022244908A1 (ko) 항-bcam 항체 또는 그의 항원 결합 단편
WO2019235856A1 (ko) Tie2에 결합하는 항체 및 이의 용도
WO2021235696A1 (ko) Cd22에 특이적인 항체 및 이의 용도
WO2020242200A1 (ko) 엔도텔린 수용체 a 결합력이 향상된 항체
WO2021096275A1 (ko) 변형된 인터루킨-7 및 tgf 베타 수용체 ii를 포함하는 융합단백질 및 이의 용도
WO2023043123A1 (ko) Fcγrⅲa 선택적 결합력 향상 당화 fc 변이체들
WO2022181992A1 (ko) Cd22에 특이적인 인간화 항체 및 이의 용도
WO2021153979A1 (ko) 항-taa 항체, 항-pd-l1 항체 및 il-2를 포함하는 융합단백질 및 이의 용도
WO2019088658A1 (ko) Scf 및 갈렉틴-1을 표적으로 하는 이중표적항체 및 그 용도
WO2022131889A1 (ko) Taci 단백질의 용도
WO2023182866A1 (ko) Hla-g 특이적 항체 및 이의 용도
JPWO2019209078A5 (https=)
WO2023158027A1 (en) A fusion protein comprising an antigen binding domain and a cytokine trimer domain

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19793399

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2020559369

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2019793399

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2019793399

Country of ref document: EP

Effective date: 20201126

WWW Wipo information: withdrawn in national office

Ref document number: 2019793399

Country of ref document: EP